1
|
Mishra A, Oberoi AS, Deo S, Sharma J, Gogia A, Sharma DN, Mathur S, Dhamija E. Bilateral Breast Cancer: Clinical Profile and Management. Indian J Surg Oncol 2023; 14:651-658. [PMID: 37900630 PMCID: PMC10611650 DOI: 10.1007/s13193-023-01731-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Accepted: 02/27/2023] [Indexed: 03/09/2023] Open
Abstract
There is paucity of literature regarding the demography, histopathology, management, and outcomes of bilateral breast cancer (BBC). We present our experience of treating 127 BBC with multimodality management. An audit of prospectively maintained computerized breast cancer database of the department of surgical oncology at a tertiary care center was performed. Demography, clinical profile, molecular sub-types, treatment patterns, and outcomes were analyzed. A total 127 patients presented with BBC between 1992 and 2019. Ninety-four had metachronous (MBBC) and 33 had synchronous breast cancer (SBBC). Most contralateral breast cancer (CBC) patients had early-stage breast cancer in comparison to the index side cancer (37% vs 32%). Ninety-four patients underwent bilateral mastectomy and only 18 patients underwent bilateral breast conservation. Seventy-one patients undergoing BCS and surgery for LABC were given postoperative radiotherapy. All patients received adjuvant chemo- and/or hormonal therapy both for index and CBC based on the stage and hormone receptor status. Thirty-three percent of patients had either locoregional or distant relapse. The 5-year overall survival (OS) and 5-year disease-free survival (DFS) of the entire cohort were 86.6% and 68.4% respectively. There was no difference in the OS and DFS between SBBC and MBBC. The incidence of BBC is expected to increase with effective diagnostic and therapeutic interventions and improving survival. Patients require individualized treatment planning in a multidisciplinary treatment setting.
Collapse
Affiliation(s)
- Ashutosh Mishra
- Department of Surgical Oncology, BRA-IRCH, AIIMS, New Delhi, India
| | | | | | - Jyoti Sharma
- Department of Surgical Oncology, BRA-IRCH, AIIMS, New Delhi, India
| | - Ajay Gogia
- Department of Medical Oncology, BRA-IRCH, AIIMS, New Delhi, India
| | - D. N. Sharma
- Department of Radiation Oncology, BRA-IRCH, AIIMS, New Delhi, India
| | | | - Ekta Dhamija
- Department of Radiology, AIIMS, New Delhi, India
| |
Collapse
|
2
|
Iyer P, Radhakrishnan V, Krishnamurthy A, Dhanushkodi M, V. S, Ananthi B, Selvaluxmy G. Real-World Experience of Treating Young Adult Patients with Breast Cancer from a Single Center in Southern India. South Asian J Cancer 2022; 11:105-111. [DOI: 10.1055/s-0041-1735481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
Background Breast cancer in young adults is rare and accounts for 5 to 6% of all cancers in this age group. We conducted the present study to look at the demographic features, clinical presentation, and outcomes in this group of patients treated at our center.
Patients and Methods The study included breast cancer patients between the age of 15 and 30 years treated at our institute from January 2009 to December 2016. Data were analyzed retrospectively from case records. Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan–Meier method.
Results Young adult breast cancers were reported in 145 out of 6,000 patients (2.41%) diagnosed with breast cancer in the study period. The median age of the patients was 29 years (range: 21–30 years). Stage I, II, III, and IV was observed in 3.4, 33.7, 46.2, and 16.5% of patients, respectively. The median follow-up was 45 months (range: 1.7–128.1 months). The 5-year EFS and OS for stage I, II, III, and IV was 100, 74.5, 47.9, and 0% and 100, 90.8, 55.1, and 0%, respectively. On univariate analysis, stage of the disease and pregnancy-associated breast cancers were found to have a significant association with decreased EFS and OS (p < 0.001, p = 0.008 and p < 0.001, p = 0.001, respectively). On multivariate analysis, stage of disease and pregnancy-associated breast cancers remained significant predictors of EFS and OS.
Conclusion Breast cancers in young adults are rare but need to be diagnosed at an early stage to improve survival. Pregnancy-associated breast cancers need to be managed optimally without delay owing to their aggressive tumor biology.
Collapse
Affiliation(s)
- Priya Iyer
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Venkatraman Radhakrishnan
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Arvind Krishnamurthy
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Manikandan Dhanushkodi
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Sridevi V.
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Balasubramanian Ananthi
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| | - Ganeshraja Selvaluxmy
- Departments of Radiation Oncology, Medical Oncology and Surgical Oncology, Cancer Institute (WIA, Chennai, Tamil Nadu, India
| |
Collapse
|
3
|
Bajpai J, Ventrapati P, Joshi S, Wadasadawala T, Rath S, Pathak R, Nandhana R, Mohanty S, Chougle Q, Engineer M, Abraham N, Ghosh J, Nair N, Gulia S, Popat P, A P, Sheth T, Desai S, Thakur M, Rangrajan V, Parmar V, Sarin R, Gupta S, Badwe RA. Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India. Breast 2021; 60:177-184. [PMID: 34655887 PMCID: PMC8527043 DOI: 10.1016/j.breast.2021.09.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/26/2021] [Accepted: 09/27/2021] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Young (≤40 years) breast cancers (YBC) are uncommon, inadequately represented in trials and have unique concerns and merit studying. METHODS The YBC treated with a curative intent between 2015 and 2016 at our institute were analysed. RESULTS There were 1228 patients with a median age of 36 (12-40) years; 38 (3.1%) had Stage I, 455 (37.1%) - II, 692 (56.3%) -III, and remaining 43 (3.5%) Stage IV (oligo-metastatic) disease; 927 (75.5%) were node positive; 422 (34.4%) were Triple negatives (TNBC), 331 (27%) were HER-2 positive. There were 549 (48.2%) breast conservations and 591 (51.8%) mastectomies of which 62 (10.4%) underwent breast reconstruction. 1143 women received chemotherapy, 617 (53.9%) received as neoadjuvant and 142 (23.1%) had pathological complete response; 934 (81.9%) received adjuvant radiotherapy. At the median follow-up of 48 (0-131) months, 5-year overall and disease-free survival was 79.6% (76.8-82.5) and 59.1% (55.8-62.6). For stage I, II, III and IV, the 5-year overall-survival was 100%, 86.7% (82.8-90.6), 77.3% (73.4-81.2), 69.7% (52.5-86.9) and disease-free survival was 94% (85.9-100), 65.9% (60.3-71.5), 55% (50.5-59.5), and 29.6% (14-45.2) respectively. On multivariate analysis, TNBC and HER-2+ subgroups had poorer survival (p = 0.0035). 25 patients had BRCA mutations with a 5-year DFS of 65.1% (95% CI:43.6-86.6). Fertility preservation was administered in 104 (8.5%) patients; seven women conceived and 5 had live births. Significant postmenopausal symptoms were present in 153 (13%) patients. CONCLUSION More than half of the YBC in India were diagnosed at an advanced stage with aggressive features leading to suboptimal outcomes. Awareness via national registry and early diagnosis is highly warranted. Menopausal symptoms and fertility issues are prevalent and demand special focus.
Collapse
Affiliation(s)
- Jyoti Bajpai
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India.
| | - Pradeep Ventrapati
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Shalaka Joshi
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Tabassum Wadasadawala
- Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Sushmita Rath
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Rima Pathak
- Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Ravindra Nandhana
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Samarpita Mohanty
- Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Qurratulain Chougle
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Mitchelle Engineer
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Nissie Abraham
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Jaya Ghosh
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Nita Nair
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Seema Gulia
- Department of Medical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Palak Popat
- Department of Radiology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Patil A
- Department of Surgical Pathology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Tanuja Sheth
- Department of Surgical Pathology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Sangeeta Desai
- Department of Surgical Pathology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Meenakshi Thakur
- Department of Surgical Pathology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Venkatesh Rangrajan
- Department of Surgical Pathology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - Vani Parmar
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - R Sarin
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - S Gupta
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| | - R A Badwe
- Department of Surgical Oncology, Tata Memorial Centre, Mumbai, India; Homi Bhabha National Institute, India
| |
Collapse
|
4
|
Abdulwassi HK, Amer IT, Alhibshi AH, Alnajjar AA, Bahatheq AK, Trabulsi NH, Nassif MO. Recurrence rates and long-term survival factors in young women with breast cancer. Saudi Med J 2021; 41:393-399. [PMID: 32291426 PMCID: PMC7841605 DOI: 10.15537/smj.2020.4.24987] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Objectives: To evaluate the factors related to breast cancer (BC) recurrence as well as survival in women ≤40 years old. Methods: This is a retrospective medical record review of women aged ≤40 years diagnosed with BC stages I to III between January 2009 and June 2017 at King Abdulaziz University Hospital (KAUH), Jeddah, Saudi Arabia. Demographic data collected included patients’ initial presentation (including age and date of diagnosis), imaging studies, tumor characteristics, type of surgery, systemic therapy (if any) received, and site of first recurrence. Data was analyzed to assess recurrence rate, disease-free survival (DFS), and overall survival (OS), and determine associated factors. Descriptive statistics were used to calculate the mean, median, standard deviation, and quartiles. Chi-square test was performed to test the association between 2 variables. Kaplan-Meier analyses were performed to assess survival distribution. Results: A total of 117 patients were included for analysis. Median follow-up was 16 months (range 0 to 99). Five-year DFS 57% and OS was 89%. Adjuvant chemotherapy was associated with a better DFS (hazard ratio of 0.204; 95% confidence interval, 0.050 to 0.832; p=0.027). Higher tumor, node, metastasis stage was significantly associated with worse DFS (p=0.034). Fewer postoperative follow-up visits significantly predicted recurrence (p=0.003). Conclusion: We found a high risk of BC recurrence among patients at our institution. Higher cancer stage, nonuse adjuvant chemotherapy, and low follow-up rate were significant predictive factors for recurrence.
Collapse
Affiliation(s)
- Hassan K Abdulwassi
- Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. E-mail.
| | | | | | | | | | | | | |
Collapse
|
5
|
Hariharan N, Rao TS, Naidu CK, Raju KVVN, Rajappa S, Ayyagari S, Krishnamohan MVT, Murthy S, Suryadevara A, Boleneni N. The Impact of Stage and Molecular Subtypes on Survival Outcomes in Young Women with Breast Cancer. J Adolesc Young Adult Oncol 2019; 8:628-634. [PMID: 31259658 DOI: 10.1089/jayao.2019.0023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Young women form a unique cohort in breast cancer, with evidence suggesting a later stage at presentation with more aggressive cancers. We aimed at evaluating the prognostic significance of young age and the impact of stage and molecular subtypes on survival. We conducted an audit of a prospectively maintained database at our institute between 2010 and 2014. All women with available receptor status and documented follow-up were included. The young breast cancer (YBC) cohort comprised 103 women and 230 women constituted the comparator arm (45-55 years). The median follow-up was 4 years. The YBC had a higher incidence of hormone negative tumors (61.1% vs. 46.3%, p = 0.012, significant [S]); however, both groups were similar in their stage at presentation. On classification into luminal subtypes, triple negative breast cancer was more common in the YBC cohort (50.5% vs. 29.6%, p = 0.001, S). The 5-year disease-free survival (DFS) was significantly worse in the YBC cohort (70.3% vs. 78%, p = 0.03, S). This detriment appeared to be significantly more in women presenting with operable breast cancer (77.2% vs. 82.6%, p = 0.012, S). Among the Luminal subtypes, there was no significant difference in the DFS between the two groups. Young age is a negative prognostic factor among women presenting with breast cancer. Further studies are required to evaluate whether any specific stage or molecular sub-type is particularly vulnerable to a poor outcome despite treatment.
Collapse
Affiliation(s)
- Nisha Hariharan
- Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - T Subramanyeshwar Rao
- Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Chandra K Naidu
- Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - K V V N Raju
- Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Senthil Rajappa
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Santa Ayyagari
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - M V T Krishnamohan
- Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Sudha Murthy
- Department of Pathology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Aparna Suryadevara
- Department of Radiation Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| | - Naren Boleneni
- Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
| |
Collapse
|
6
|
Differences in Breast Cancer Stage at Diagnosis by Ethnicity, Insurance Status, and Family Income in Young Women in the USA. J Racial Ethn Health Disparities 2019; 6:909-916. [PMID: 31102102 DOI: 10.1007/s40615-019-00591-y] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Revised: 03/29/2019] [Accepted: 04/03/2019] [Indexed: 12/20/2022]
Abstract
PURPOSE Describe the clinical and epidemiological data from young women with breast cancer and determine the association between ethnicity, insurance status, family income, and breast cancer stage at the diagnosis in this population. METHODS Women under the age of 40 diagnosed with invasive breast cancer from 2010 to 2014 and identified in the Surveillance, Epidemiology, and End Results (SEER) 18 registries database were included. Binary logistic regression was applied in order to estimate the odds ratios (ORs) for factors that were potentially predictive for receiving a breast cancer diagnosis at stage I. RESULTS Of 14,379 young women with invasive breast cancer, 70.9% of the patients were white, 15.9% black, and 13.2% classified as other ethnicity (American Indian, Asian, Pacific Islander). The initial clinical stage at diagnosis was stage I in 28.2%, II in 45.2%, III in 19.0%, and IV in 7.6%. The chi-square test showed a significant association between clinical stage at diagnosis and family income (p < 0.0001), insurance status (p < 0.0001), and ethnicity (p < 0.0001). The ORs for being diagnosed at stage I, regarding different factors, revealed that women with family income higher than US$ 85,000 were more likely to be diagnosed with stage I (OR [95%CI], 1.306 [1.173-1.454]; p value < 0.0001) when compared with patients with family income of less than US$ 60,000. Black women were less likely to be diagnosed with stage I (OR [95%CI], 0.676 [0.605-0.755]; p value < 0.0001), when compared with white women. Uninsured women were less likely to be diagnosed with stage I (OR [95%CI], 0.586 [0.529-0.648]; p value < 0.0001) when compared with women with insurance coverage. CONCLUSION Among young US women diagnosed with invasive breast cancer, most of them presented early stage disease. Women with black ethnicity, low income, and uninsured are at risk for late-stage presentation. Improvements in strategies to allow earlier breast cancer diagnosis in these at risk population are urged.
Collapse
|
7
|
Parmar V. Rising Incidence of Breast Cancer in the Young Fertile Indian Population-a Reality Check. Indian J Surg Oncol 2018; 9:296-299. [PMID: 30287986 PMCID: PMC6154358 DOI: 10.1007/s13193-018-0800-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 07/13/2018] [Indexed: 12/18/2022] Open
Abstract
Breast cancer in India appears to be diagnosed more in the young women, but whether this is an actual higher incidence, and hence a matter of concern, needs more clarity, and the extent to which correctable measures can be taken to reduce or overcome this additional disease burden, if any, has to be better understood. The article analyzes these and more in a systematic manner and highlights the important issues in the very young women which makes the clinical management of breast cancer more complex.
Collapse
Affiliation(s)
- Vani Parmar
- Breast Unit, Surgical Oncology, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, India
| |
Collapse
|
8
|
Darwish AD, Helal AM, Aly El-Din NH, Solaiman LL, Amin A. Breast cancer in women aging 35 years old and younger: The Egyptian National Cancer Institute (NCI) experience. Breast 2016; 31:1-8. [PMID: 27771499 DOI: 10.1016/j.breast.2016.09.018] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Revised: 09/24/2016] [Accepted: 09/27/2016] [Indexed: 12/27/2022] Open
Abstract
OBJECTIVE The aim is to identify the epidemiological and clinicopathological features associated with young breast cancer (BC) patients and to discuss factors affecting tumor recurrence and DFS. PATIENTS & METHODS A retrospective analysis was conducted based on medical records from young females patients aged ≤35 years with pathologically confirmed primary breast cancer treated during 2008-2010 at NCI. Cases with non invasive cancer and non carcinoma histology are excluded. RESULTS Of the 5408 cases diagnosed with breast cancer, 554 were young. Four hundred & fifty eight patients representing 9.2% were within our inclusion criteria. Almost half of the patients (45.9%) presented with stage III. Axillary nodes involvement was in 63.9%, 83.3% were grade 2. More than one quarter of tumors was hormone receptors negative (28.8%) & Her2 was over-expressed in 30%. Mastectomy was offered in 72% while conservative breast surgery in 26%, 69.2% received chemotherapy either adjuvant, neoadjuvant or both, 82.5% received adjuvant radiotherapy, 68.6% received hormonal therapy. Metastatic disease developed in 51.3%, with 31% having more than one site of metastases. After a median follow up period of 66 months, the median DFS of patients was 60 months. The median DFS was significantly shorter among patients with positive lymph nodes (P < 0.0001), ER negative disease (P = 0.045) and stage III disease (P < 0.0001). CONCLUSION Breast cancer in young women is aggressive from the time of diagnosis. Our results provide baseline data of young BC in the Middle East & North Africa region; thus, contributing to future epidemiological and hospital-based researches.
Collapse
Affiliation(s)
- A D Darwish
- Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
| | - A M Helal
- Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
| | - N H Aly El-Din
- Biostatistics & Epidemiology, National Cancer Institute, Cairo University, Cairo, Egypt
| | | | - A Amin
- Radiation Oncology and Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt
| |
Collapse
|